The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Expression of Sodium-Iodide Symporter (NIS) in Thyroid Nodules: Comparison of RT-PCR and Immunohistochemical Staining Methods

갑상선 결절에서 Sodium Iodide Symporter (NIS)의 발현: RT-PCR방법과 면역조직화학염색법의 비교

  • Bae, Sang-Kyun (Department of Nuclear Medicine, Inje University College of Medicine) ;
  • Lee, Kang-Dae (Department of Head & Neck Surgery, Kosin University College of Medicine) ;
  • Chang, Hee-Kyung (Department of Pathology, Kosin University College of Medicine)
  • 배상균 (인제대학교 의과대학 핵의학교실) ;
  • 이강대 (고신대학교 의과대학 이비인후과학교실) ;
  • 장희경 (고신대학교 의과대학 병리학교실)
  • Published : 2004.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The sodium-iodide symporter (NIS) expression is an important factor in determining the sensitivity of radioiodine therapy in well-differentiated thyroid cancers. Several previous studies for the expression of NIS in thyroid tissues show diverse results. To investigate whether there is difference between methods in determining the expression of NIS in thyroid tissues of patients with thyroid nodules, we measured the expression ot NIS using two different methods (RT-PCR and immunoshistochemical staining) and compared the results. Materials & Methods: We measured the expression of NIS by reverse transcriptase-polymerase chain reaction (RT-PCR) and also by immunohistochemical staining using anti-NIS antibody in thyroid cancers and other benign thyroid diseases. We compared the results of each method. We included 19 papillary carcinomas, 1 follicular carcinoma, 7 medullary carcinoma, 4 adenomas and 7 nodular hyperplasias. Results: By RT-PCR analysis, 10 of 19 papillary carcinomas expressed NIS, but 1 follicular cancer didn't express NIS. By immunohistochemical staining, 15 of 19 papaillary carcinomas express NIS, but 1 follicular lancer didn't express NIS. There was a significant correlation between the semiquautitative results of RT-PCR and immunohistochemical staining of NIS expression. (p<0.01) Conclusion: Our data demonstrated that the expression of NIS in thyroid cancers and other benign diseases investigated by RT-PCR and immunohistochemical staining correlated well each other. However, by immunohistochemical staining, more NIS expression was found.

목적: 갑상선세포에서 요오드의 섭취는 갑상선호르몬 합성의 첫 단계이며, sodium iodide symporter (NIS)라는 세포막 단백질에 의해 이루어지는 것으로 알려져 있고 NIS 유전자가 클로닝됨으로써 NIS 발현을 직접 관찰하는 것이 가능해졌다. 하지만, 갑상선암을 비롯한 갑상선 결절과 정상 조직에서의 NIS 발현은 검사방법과 대상에 따라 아주 다양한 결과를 보이고 있다. 따라서 이 연구에서는 갑상선암을 비롯한 여러 갑상선질환에서 NIS의 발현여부와 정도를 두 가지 서로 다른 RT-PCR방법과 면역조직화학염색법으로 조사하여 비교하였다. 대상 및 방법: 갑상선절제술을 받은 32명의 조직을 이용하였다. 술후 병리학적 진단은 유두암 19명, 여포암 1명, 수질암 1명, 선종 4명, 선종양 갑상선종 7명이었다. RT-PCR방법을 이용하여 갑상선글로불린, NIS, 갑상선과산화효소의 발현을 관찰하였고, 항NIS 항체를 이용하여 면역조직화학염색을 시행하여 NIS 발현 정도를 반정량적으로 평가하고, 그 결과를 각각 비교하였다. 결과: RT-PCR의 결과에서 유두암 19명중 10예에서 NIS의 발현이 있었다. 여포암 1예와 수질암 1예는 NIS 발현이 없었다. 선종 4명중 2예, 선종양 갑상선종 7명중 4예에서 NIS의 발현이 있었다. 면역조직화학염색법으로는 유두암 19명중 15예에서 발현이 있었고, 여포암 1예는 발현이 없었다. 선종 4예중 3예, 선종양 갑상선종 7예중 6예에서 발현이 있었다. RT-PCR방법에 의한 NIS의 발현 정도와 면역조직화학염색의 정도를 반정량적으로 평가하여 비교한 결과 각 검사의 결과 사이에 유의한 양의 상관관계가 있었다(p<0.001). 결론: RT-PCR방법과 면역조직화학염색법으로 조사한 NIS의 발현 정도는 양의 상관관계가 있었으나, RT-PCR방법에 비해 면역조직화학염색법으로 NIS발현을 더 많이 찾을 수 있었다.

Keywords

References

  1. Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocr Rev 1994;15:500-15
  2. Spitzweg C, Heufelder AE. Update on the thyroid sodium iodide symporter: A novel thyroid antigen emerging on the horizon. Eur J Endocrinol 1997;137:22-3 https://doi.org/10.1530/eje.0.1370022
  3. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-60 https://doi.org/10.1038/379458a0
  4. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 1996;226:339-45 https://doi.org/10.1006/bbrc.1996.1358
  5. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998;83:2493-6 https://doi.org/10.1210/jc.83.7.2493
  6. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, et al. Expression of the $Na^+/I^-$ symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228-34 https://doi.org/10.1210/jc.84.9.3228
  7. Ryu KY, Senokozlieff ME, Smanik PA, Wong MG, Siperstein AE, Duh QY, et al. Development of reverse transcription-competitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter. Thyroid 1999;9:405-9 https://doi.org/10.1089/thy.1999.9.405
  8. Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 2000;10:211-7 https://doi.org/10.1089/thy.2000.10.211
  9. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, et al. $Na^+/I^-$ symporter distribution in human thyroid tissues: An immunohistochemical study. J Clin Endocrinol Metab 1998;83:4102-6 https://doi.org/10.1210/jc.83.11.4102
  10. Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR, et al. An immunohistochemical study of $Na^+/I^-$ symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998;139:4416-9 https://doi.org/10.1210/en.139.10.4416
  11. Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, et al. Monoclonal antibodies against the human sodium iodide symporter: Utility for immunocytochemistry of thyroid cancer. J Endocrinol 1999; 163:495-504 https://doi.org/10.1677/joe.0.1630495
  12. Castro MR, Bergert ER, Beito TG, McIver B, Goellner JR, Morris JC. Development of monoclonal antibodies against the human sodium iodide symporter: Immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 1999;84:2957-62 https://doi.org/10.1210/jc.84.8.2957
  13. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997;138:3555-8 https://doi.org/10.1210/en.138.8.3555
  14. Mian C, Lacroix L, Alzieu L, Nocera M, Talbot M, Bidart JM, et al. Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 2001;11:825-30 https://doi.org/10.1089/105072501316973073
  15. Ringel MD, Anderson J, Souza SL, Burch HB, Tambascia M, Shriver CD, et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001; 14:289-96 https://doi.org/10.1038/modpathol.3880305
  16. Liou MJ, Lin JD, Chan EC, Liu FH, Chao TC, Weng HF. Detection of mrna of sodium iodide symporter in benign and malignant human thyroid tissues. Cancer Lett 2000;160:75-80 https://doi.org/10.1016/S0304-3835(00)00565-6
  17. Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 1998;101:1296-300 https://doi.org/10.1172/JCI1259
  18. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 1999;84:4178-84 https://doi.org/10.1210/jc.84.11.4178
  19. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639-45 https://doi.org/10.1007/s002590100509
  20. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: Correlation with radioiodine uptake. J Clin Endocrinol Metab 2001;86:5627-32 https://doi.org/10.1210/jc.86.11.5627
  21. Saito T, Endo T, Kawaguchi A, Ikeda M, Nakazato M, Kogai T, et al. Increased expression of the $Na^+/I^-$ symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue. J Clin Endocrinol Metab 1997;82:3331-6 https://doi.org/10.1210/jc.82.10.3331
  22. Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997;138:2227-32 https://doi.org/10.1210/en.138.6.2227
  23. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N. $Na^+/I^-$ symport activity is present in membrane vesicles from thyrotropindeprived non-I(-)-transporting cultured thyroid cells. Proc Natl Acad Sci U S A 1994;91:3789-93 https://doi.org/10.1073/pnas.91.9.3789
  24. Goldman JM, Line BR, Aamodt RL, Robbins J. Influence of triiodothyronine withdrawal time on $^{131}I$ uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980;50:734-9 https://doi.org/10.1210/jcem-50-4-734
  25. Schlumberger M, Charbord P, Fragu P, Gardet P, Lumbroso J, Parmentier C, et al. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab 1983;57:148-51 https://doi.org/10.1210/jcem-57-1-148
  26. Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, Porra V, Berger-Dutrieux N, Decaussin M, et al. Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol 2004;165:25-34 https://doi.org/10.1016/S0002-9440(10)63272-5